ALISO VIEJO, Calif., April 10, 2008 (PRIME NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it has received approval to apply the CE Mark to its SenoSonix(tm) with EnCor, an integration of its EnCor(r) breast biopsy system with a state-of-the-art ultrasound imaging system. The device incorporates SenoRx's proprietary EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corporation of Canada. The CE Mark is required for sales in countries within the European Economic Community. SenoRx and Ultrasonix had previously announced the receipt of 510(k) clearance in the United States for the SenoSonix system in October 2007.
